Trials / Completed
CompletedNCT00903786
A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to investigate the safety and tolerability of perampanel in long- term treatment in the patients with refractory partial epilepsy (uncontrolled with other anti-epileptic drugs) who completed Week 10 of Phase II Study E2007-J081-231 study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | perampanel | Patients will receive the same oral dosage (2 mg up to 12 mg once daily before bedtime) as used in the maintenance period of Study 231. |
Timeline
- Start date
- 2009-06-17
- Primary completion
- 2016-08-08
- Completion
- 2016-10-31
- First posted
- 2009-05-18
- Last updated
- 2018-08-29
- Results posted
- 2018-08-29
Locations
9 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00903786. Inclusion in this directory is not an endorsement.